Skip to content

Investigating the Safety and Efficacy of Human Umbilical Cord Blood Serum (HUCBS) Microneedle compared to only Microneedling for Acne Scar treatment

Investigating the Safety and Efficacy of Human Umbilical Cord Blood Serum (HUCBS) Microneedle compared to only Microneedling for Acne Scar treatment (clinical trial phase ?)

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221130056672N7
Enrollment
30
Registered
2024-03-10
Start date
2024-04-20
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Scar.

Interventions

Intervention 1: The first group: three times every three weeks (days 1-21-42) on one side of the face MN alone and on the other side MN + HUCBS with a dose of 2% microneedling. Intervention 2: The sec

Sponsors

Research Vice President of Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients with rolling acne scars with different severity (according to the Goodman grading system) Complete consent of the patient to participate in the plan Age 18 years and above and less than 50 years.

Exclusion criteria

Exclusion criteria: Being positive in terms of the following: active inflammatory acne, active herpes labialis, local infections in the treatment area, prone to keloids, malignancy, pregnancy, breastfeeding, taking drugs that can affect bleeding or clotting mechanisms, immunosuppression, use of local and systemic steroids, systemic diseases), high blood pressure, diabetes, heart, kidney and liver diseases) Using peels 4 weeks before treatment It should not be done in areas where botulinum injection has been done due to the possibility of microneedle toxin release Positive history of bleeding or platelet disorder, positive history of major surgery in the last 6 months, presence of any acute facial infection such as herpes, folliculitis. HIV patients, HBsAg or any chronic disease

Design outcomes

Primary

MeasureTime frame
The improvement rate of the depth of acne scars and the amount of skin spots and pores. Timepoint: Biometric tests will be done on the first day before the treatment and one month after the treatment. Method of measurement: Visioface.;The thickness and density of the skin. Timepoint: Biometric tests will be done on the first day before the treatment and one month after the treatment. Method of measurement: Sonography.;Elasticity and plasticity of the skin. Timepoint: Biometric tests will be done on the first day before the treatment and one month after the treatment. Method of measurement: Cutometer.

Secondary

MeasureTime frame
Safety and Efficacy. Timepoint: Safety checks are done before and after each treatment. Method of measurement: Patient history and the examination and diagnosis of the attending physician.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEhsan Taghiabadi

Tehran University of Medical Sciences

etaghiabadi@sina.tums.ac.ir+98 21 2665 7438

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026